Fromtling R A, Galgiani J N, Pfaller M A, Espinel-Ingroff A, Bartizal K F, Bartlett M S, Body B A, Frey C, Hall G, Roberts G D
Department of Public Policy Management, Merck & Co., Inc., Whitehouse Station, New Jersey 08889-0100, USA.
Antimicrob Agents Chemother. 1993 Jan;37(1):39-45. doi: 10.1128/AAC.37.1.39.
Thirteen laboratories collaborated to optimize interlaboratory agreement of results of a broth macrodilution procedure for testing three classes of antifungal drugs against pathogenic yeasts. The activities of amphotericin B, flucytosine, and ketoconazole were tested against 100 coded isolates of Candida albicans, Candida tropicalis, Candida parapsilosis, Candida lusitaniae, Torulopsis (Candida) glabrata, and Cryptococcus neoformans. Two starting yeast inoculum sizes (5 x 10(4) and 2.5 x 10(3) cells per ml) were compared, and readings were taken after 24 and 48 h of incubation. All other test conditions were standardized. The resultant turbidities in all tubes were estimated visually on a scale from 0 to 4+ turbidity, and MIC-0, MIC-1, and MIC-2 were defined as the lowest drug concentrations that reduced growth to 0, 1+, or 2+ turbidity, respectively. For flucytosine, agreement among laboratories varied between 57 and 87% for different inocula, times of incubation, and end point criteria. Agreement was maximized (85%) when the lower inoculum was incubated for 2 days and the MICs were defined as 1+ turbidity or less. For amphotericin B, variations in test conditions produced much smaller differences in interlaboratory agreement. For ketoconazole, interlaboratory agreement was poorer by all end point criteria. However, MIC-2 endpoints distinguished T. glabrata as resistant compared with the other species. Overall, the studies indicated that readings from the lower inoculum obtained on the second day of reading result in the greatest interlaboratory agreement. In combination with data from previous multicenter studies (National Committee for Clinical Laboratory Standards, Antifungal Susceptibility Testing: Committee Report, Vol. 5, No. 17, 1988; M. A. Pfaller, L. Burmeister, M. S. Bartlett, and M. G. Rinaldi, J. Clin. Microbiol. 26:1437-1441, 1988; M. A. Pfaller, M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B.A. Body, A. Espinel-Ingroff, R.A. Fromtling, G.S. Hall, C.E. Hughes, F. C. Odds, and A. M. SUgar, J. Clin. Microbiol. 34:1648-1654, 1990), these findings will be used by the National Committee for Clinical Laboratory Standards to develop a standardized method for in vitro antifungal susceptibility testing for yeasts.
13个实验室合作,优化了用于检测三类抗真菌药物对致病性酵母的肉汤稀释法结果的实验室间一致性。对两性霉素B、氟胞嘧啶和酮康唑的活性进行了检测,受试对象为100株编码的白色念珠菌、热带念珠菌、近平滑念珠菌、葡萄牙念珠菌、光滑念珠菌(念珠菌属)和新生隐球菌。比较了两种起始酵母接种量(每毫升5×10⁴和2.5×10³个细胞),并在孵育24小时和48小时后进行读数。所有其他测试条件均标准化。目视估计所有试管中产生的浊度,浊度范围为0至4+,MIC-0、MIC-1和MIC-2分别定义为将生长降低至0、1+或2+浊度的最低药物浓度。对于氟胞嘧啶,不同接种量、孵育时间和终点标准下,实验室间的一致性在57%至87%之间变化。当较低接种量孵育2天且MIC定义为1+浊度或更低时,一致性最高(85%)。对于两性霉素B,测试条件的变化在实验室间一致性方面产生的差异要小得多。对于酮康唑,根据所有终点标准,实验室间的一致性较差。然而,与其他菌种相比,MIC-2终点可将光滑念珠菌鉴定为耐药。总体而言,研究表明,在第二天读取较低接种量的读数可实现最大的实验室间一致性。结合之前多中心研究的数据(美国国家临床实验室标准委员会,《抗真菌药敏试验:委员会报告》,第5卷,第17号,1988年;M.A.普法勒、L.伯迈斯特、M.S.巴特利特和M.G.里纳尔迪,《临床微生物学杂志》26:1437 - 1441,1988年;M.A.普法勒、M.G.里纳尔迪、J.N.加尔贾尼、M.S.巴特利特、B.A.博迪、A.埃斯皮内尔 - 英格罗夫、R.A.弗罗姆特林、G.S.霍尔、C.E.休斯、F.C.奥兹和A.M.苏加,《临床微生物学杂志》34:1648 - 1654,1990年),这些发现将被美国国家临床实验室标准委员会用于制定酵母体外抗真菌药敏试验的标准化方法。